Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Nov;74(21):10202-6.
doi: 10.1128/jvi.74.21.10202-10206.2000.

Restricting expression prolongs expression of foreign genes introduced into animals by retroviruses

Affiliations

Restricting expression prolongs expression of foreign genes introduced into animals by retroviruses

V B Pinto et al. J Virol. 2000 Nov.

Abstract

If foreign genes are ubiquitously expressed in mice using a viral vector, expression is abrogated by CD8(+) cells in 2 to 4 weeks. However, if the expression of the genes is confined to skeletal muscle cells, the CD8(+) T-cell response is much weaker and expression is maintained for more than 6 weeks. These data show that restricting the expression of foreign genes to skeletal muscle cells and presumably to other cells that are inefficient at antigen presentation can prolong the expression of a foreign gene product.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Schematic representation of the ASLV proviral DNAs and mRNAs coding for the reporter genes, AP and OVAM257–264. The viral genes gag, pol, and env are shown (not to scale), as are the genes AP and OVAM257–264. Internal promoters are shown as arrowheads. The positions of splice donors (SD) and splice acceptors (SA) are also shown. The retroviral vectors RCASBP(A) and RCANBP(A) and the Cla12 adapter plasmid have been described elsewhere (18, 27), as has RCASBP/AP(A) (10). The αsk-actin promoter was cloned into the ClaI-EcoRI site of the Cla12 adapter plasmid, and the AP cDNA was cloned into the EcoRI-SalI site of the same adapter plasmid. The ClaI fragment containing the αsk-actin AP fragment was excised from the Cla12 adapter and cloned into the ClaI site of RCANBP(A) to produce RCANBP/αsk-actin AP(A). The MC1 promoter, kindly provided by Mario Capecchi, contains a polyomavirus enhancer and a minimal TK promoter. The two oligonucleotides 5′-CCCGCCTCTAGACTCGAGCAGTGTGGTTTTCAAGAGG-3′ and 5′-CCCGCCGTCGACTCAGAGCTTCTCGAAGTTGATGATCGACATGGTTGCAGGGTCGCTCGG-3′ were used to produce the MC1 OvaM257–264 PCR product. This product was cloned into the XbaI-SalI site of Cla12 that contained AP in the EcoRI site. The ClaI fragment that contained the AP-MC1-OvaM257–264 was excised from the Cla12 adapter and cloned into the ClaI site of RCASBP(A) to produce RCASBP/AP-MC1-OvaM257–264(A). The αsk-actin promoter was cloned into the SmaI-EcoRI site of pBluescript SK(+). The two oligonucleotides 5′-AATTCACCATGTCGATCATCAACTTCGAGAAGCTCTGAG-3′ and 5′-TCGACTCAGAGCTTCTCGAAGTTGATGATCGACATGGTG-3′ that code for the peptide were cloned into the EcoRI-SalI site of pBluescript SK(+) that contained the αsk-actin promoter. The XbaI-SalI fragment that contained the αsk-actin promoter linked to OvaM257–264 was cloned into the XbaI-Sa1I site of Cla12 that contained AP in the EcoRI site. The ClaI fragment that contained the AP–αsk-actin–OvaM257–264 segment was excised from the Cla12 adapter and cloned into the ClaI site of RCASBP(A) to produce RCASBP/AP–αsk-actin–OvaM257–264(A).
FIG. 2
FIG. 2
βAKE mice infected with RCASBP/AP(A). The mice were sacrificed on days 14, 28, and 42, and their legs were stained for AP (see the text). Muscle fibers that express AP can be seen as purple streaks.
FIG. 3
FIG. 3
Splenocytes from adult C57BL/6 mice infected with OVAM257–264 VV (a) or 2-week-old βAKE mice injected on day 1 with RCASBP/AP-MC1 OVAM257–264(A) (b) virus-producing DF-1 cells were restimulated in vitro with 0.1 μM SIINFEKL and subsequently assayed for cytolytic activity against control (open boxes) or peptide-pulsed (closed boxes) targets at various E:T ratios (see the text).
FIG. 4
FIG. 4
TAP1−/− mice carrying the Tva receptor infected with RCASBP/AP(A). The mice were sacrificed on days 14, 28, and 49, and their legs were stained for AP (see the text). Two of the legs (14 and 49 days) are negative for AP staining. These legs are from mice that do not have the subgroup A receptor.
FIG. 5
FIG. 5
Splenocytes from 2-week-old βAKE mice injected on day 1 with RCASBP/AP-MC1 OVAM257–264(A) virus-producing DF-1 cells (a) or 2-week-old βAKE mice injected on day 1 with RCASBP/AP-αsk OVAM257–264(A) virus-producing DF-1 cells (b) were restimulated in vitro with 0.1 μM SIINFEKL and subsequently assayed for cytolytic activity against control (open boxes) or peptide-pulsed (closed boxes) targets at various E:T ratios (see the text).
FIG. 6
FIG. 6
βAKE mice infected with RCANBP/αskAP(A). The mice were sacrificed on days 14, 28, and 42, and their legs were stained for AP.

Similar articles

Cited by

References

    1. Arai M, Scandella D, Hoyer L W. Molecular basis of factor VIII inhibition by human antibodies: antibodies that bind to factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Investig. 1989;83:1978–1984. - PMC - PubMed
    1. Bacik I, Cox J H, Anderson R, Yewdell J W, Bennink J R. Tap-independent presentation of endogenously synthesized peptides is enhanced by endocytoplasmic reticulum insertion sequences located at the amino but not carboxy terminus of the peptide. J Immunol. 1994;152:381–338. - PubMed
    1. Bevan M J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 1976;143:1283–1288. - PMC - PubMed
    1. Chen H-H, Mack L M, Kelly R, Ontell M, Kochanek S, Clemens P R. Persistence in muscle of an adenoviral vector that lacks viral genes. Proc Natl Acad Sci USA. 1997;94:1645–1650. - PMC - PubMed
    1. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992;339:594–598. - PubMed

Publication types